Bliss GVS Pharma Ltd has appointed Rahul Adakmol as its new CEO, effective July 15, 2026. The company is separating the CEO and Managing Director roles, with Narsimha Shibroor Kamath continuing as MD. This move aims to support the company's next growth phase.
Bliss GVS Pharma Appoints New CEO, Divides Executive Roles
Bliss GVS Pharma Ltd announced key management and board changes, appointing Rahul Adakmol as Chief Executive Officer and Mr. Santosh Parab as Additional Director. The company is separating the roles of CEO and Managing Director, a move aimed at supporting its future growth phases.
Reader Takeaway: New CEO brings global expansion experience; structured transition aims for growth acceleration.
What just happened
Bliss GVS Pharma Ltd has appointed Mr. Rahul Adakmol as its new Chief Executive Officer, effective July 15, 2026. Concurrently, Mr. Narsimha Shibroor Kamath will step down from the CEO role but continue as Managing Director. Mr. Santosh Parab has been appointed as an Additional Director (Non-Executive), effective July 3, 2026.
Why this matters
This leadership transition is significant as it separates the CEO and Managing Director functions. This structural change is expected to allow for more focused operational scaling under the new CEO, while the Managing Director can concentrate on strategic oversight. Investors may see this as a move to enhance governance and drive future expansion.
The backstory
Previously, Mr. Narsimha Shibroor Kamath held both the CEO and Managing Director positions. This separation represents a planned evolution in the company's leadership structure to better manage growth.
What changes now
Mr. Rahul Adakmol will now lead the operational execution as CEO, leveraging his extensive experience in sales, marketing, and global market expansion. Mr. Kamath will continue to provide strategic direction and continuity as Managing Director. Mr. Parab's appointment adds financial and governance expertise to the board.
Risks to watch
While the transition appears structured, investors will be keen to see how the new leadership team executes its strategy and integrates new roles. Any disruption during this handover period could impact operations.
Peer comparison
Separating CEO and MD roles is a common corporate governance practice among listed companies to ensure checks and balances and to allow for specialized focus in leadership.
Context metrics (time-bound)
- Mr. Rahul Adakmol's appointment as CEO is effective July 15, 2026.
- Mr. Narsimha Shibroor Kamath's resignation from CEO role is effective July 14, 2026.
- Mr. Santosh Parab's appointment as Additional Director is effective July 3, 2026.
What to track next
Investors should look for initial strategic communications from the new CEO, Mr. Adakmol, outlining his vision and priorities for Bliss GVS Pharma Ltd.